



Prothena Corporation plc
Investor Relations Department
331 Oyster Point Blvd
South San Francisco, CA 94080
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: PRTA

Last Trade:	35.13
Trade Time:	4:00 PM ET Mar 16, 2018
Change:	0.22 ↑ (+0.630%)
Day Range	34.43 - 36.03
52-Week Range	27.19 - 70.00
Volume	969,554

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a global, late-stage clinical biotechnology company establishing fully integrated research, development and commercial capabilities and focused on advancing new therapies in the neuroscience and orphan categories. Fueled by a deep scientific understanding built over decades of research in protein misfolding, we seek to fundamentally change the course of grave or currently untreatable diseases associated with this biology. Our pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Mar 12, 2018*
[Prothena to Present a Broad Range of Scientific and Health Outcomes Data at the 16th International Symposium on Amyloidosis](#)
- Mar 7, 2018*
[Prothena to Participate in the Barclays Global Healthcare Conference](#)
- Feb 14, 2018*
[Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, and Provides Financial Guidance and R&D Update](#)
- Feb 7, 2018*
[Prothena to Participate in the Leerink Partners 7th Annual Global Healthcare Conference](#)
- Feb 2, 2018*
[Prothena Announces Departure of Chief Medical Officer](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 26, 2018*
[Annual Report \(10-K\)](#)
- Mar 31, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)